Prevalence and clinical significance of serum anti-cyclic citrullinated peptide antibodies in primary Sjögren's syndrome

Abstract

Objectives: Although anti-cyclic citrullinated peptide (anti-CCP) antibody is a specific marker for rheumatoid arthritis (RA), it is also detected positively in some other rheumatological diseases including Sjögren's syndrome (SS) and even in healthy people. Studies have shown that anti-CCP guides the early diagnosis, prognosis and treatment of RA patients. SS and RA overlap syndrome are common. This study was conducted to determine the prevalence and clinical significance of serum anti-CCP in primary SS patients followed in our outpatient clinic.

Methods: Eighty-two primary SS, 100 RA patients and 100 healthy controls applied to rheumatology outpatient clinic were examined. Patients and control groups were compared in terms of demographic characteristics, laboratory results and anti-CCP.

Results: In the present study, anti-CCP was positive in 4 (4.9%) of 82 primary SS patients. In the SS group, among other autoantibodies, ANA was found to be positive at 88.8%, RF 45%, SS-A 64.6%, and SS-B 36.7%. There was no relationship between anti-CCP and joint involvement in patients with SS.

Conclusions: Anti-CCP antibody positivity can be found in SS patients. Acute phase proteins may be higher in primary SS patients with positive anti-CCP antibody. However, studies have found conflicting findings about the prevalence of erosive arthritis and the future development of RA in these patient groups.

Keywords

• Primary Sjögren's syndrome
• rheumatoid arthritis
• anti-cyclic citrullinated peptide

References

1. 1. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum 2000;29:296-304.
2. 2. Theander E, Jacobsson LT. Relationship of Sjögren’s syndrome to other connective tissue and autoimmune disorders. Rheum Dis Clin North Am 2008;34:935-47.
3. 3. Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001;47:1089-93.
4. 4. Schellekens GA, Visser H, de Jong BAW, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing anti-cyclic citrulinated peptide. Arthritis Rheum 2000;43:155-63.
5. 5. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early? A prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357-65.
6. 6. Vincent C, Nogueira L, Clavel C, Sebbag M, Serre G. Autoantibodies to citrullinated proteins: ACPA. Autoimmunity 2005;38:17-24.
7. 7. Kwok JS, Hui KH, Lee TL, Wong W, Lau YL, Wong RWS, et al. Anti-cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand J Rheumatol 2005;34:359-66.
8. 8. Kakumanu P, Yamagata H, Sobel ES, Reeves WH, Chan EKL, Satoh M. Patients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine-containing peptide. Arthritis Rheum 2008;58:1576-81.

9. 9. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
10. 10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
11. 11. Alani H, Henty JR, Thompson NL, Jury E, Ciurtin C. Systematic review and meta-analysis of the epidemiology of polyautoimmunity in Sjögren's syndrome (secondary Sjögren's syndrome) focusing on autoimmune rheumatic diseases. Scand J Rheumatol 2018;47:141-54.
12. 12. Molano-González N, Olivares-Martínez E, Anaya JM, Hernández-Molina G. Anti-citrullinated protein antibodies and arthritis in Sjögren's syndrome: a systematic review and meta-analysis. Scand J Rheumatol 2019;48:157-63.
13. 13. Maślińska M, Mańczak M, Wojciechowska B, Kwiatkowska B. The prevalence of ANA antibodies, anticentromere antibodies, and anti-cyclic citrullinated peptide antibodies in patients with primary Sjögren's syndrome compared to patients with dryness symptoms without primary Sjögren's syndrome confirmation. Reumatologia 2017;55:113-9.
14. 14. Kamali S, Polat NG, Kasapoglu E, Gul A, Ocal L, Aral O, et al. Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjögren's syndrome, and Wegener's granulomatosis. Clin Rheumatol 2005;24:673-6.
15. 15. Ryu YS, Park SH, Lee J, Kwok SK, Ju JH, Kim HY, et al. Follow-up of primary Sjogren's syndrome patients presenting positive anti-cyclic citrullinated peptides antibody. Rheumatol Int 2013;33:1443-6.
16. 16. Goeb V, Salle V, Duhaut P, ouen F, Smail A, Ducroix JP, et al. Clinical significance of autoantibodies recognizing Sjögren's syndrome A (SSA), SSB, calpastatin and alpha-fodrin in primary Sjögren's syndrome. Clin Exp Immunol 2007;148:281-7.
17. 17. Gottenberg JE, Mignot S, Nicaise-Rolland P, Cohen-Solal J, Aucouturier F, Goetz J, et al. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren's syndrome. Ann Rheum Dis 2005;64:114-7.
18. 18. Atzeni F, Sarzi-Puttini P, Lama N, Bonacci E, Bobbio-Pallavicini F, Montecucco C, et al. Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis. Arthritis Res Ther 2008;10: R51.
19. 19. Iwamoto N, Kawakami A, Tamai M, Fujikawa K, Arima K, Aramaki T, et al. Determination of the subset of Sjogren's syndrome with articular manifestations by anticyclic citrullinated peptide antibodies. J Rheumatol 2009;36:113-5.
20. 20. Mohammed K, Pope J, Le Riche N, Brintnell W, Cairns E, Coles R, et al. Association of severe inflammatory polyarthritis in primary Sjögren's syndrome: clinical, serologic, and HLA analysis. J Rheumatol 2009;36:1937-42.
21. 21. Mariette X, Criswell LA. Primary Sjögren's syndrome. N Engl J Med 2018;378:931-9.
22. 22. Fauchais AL, Ouattara B, Gondran G, Lalloue F, Petit D, Ly K, et al. Articular manifestations in primary Sjögren's syndrome: clinical significance and prognosis of 188 patients. Rheumatology (Oxford) 2010;49:1164-72.
23. 23. Guedes LKN, Leon EP, Bocate TS, Bonfiglioli KR, Lourenço SV, Bonfa E, et al. Characterizing hand and wrist ultrasound pattern in primary Sjögren's syndrome: a case-control study. Clin Rheumatol 2020;39:1907-18.
24. 24. Shabana K, Okamoto N, Sugita Y, Shindo K, Murata T, Tamai H, et al. The findings of musculoskeletal ultrasonography on primary Sjögren's syndrome patients in childhood with articular manifestations and the impact of anti-cyclic citrullinated peptide antibody. Mod Rheumatol 2019;29:821-8.
25. 25. Haga HJ, Andersen DT, Peen E. Prevalence of IgA class antibodies to cyclic citrullinated peptide (anti-CCP) in patients with primary Sjögren's syndrome, and its association to clinical manifestations. Clin Rheumatol 2011;30:369-72.
26. 26. Olivares-Martínez E, Hernández-Ramírez DF, Núñez-Álvarez CA, Liorente L, Hernandez-Molina G. α-enolase is an antigenic target in primary Sjögren's syndrome. Clin Exp Rheumatol 2019;37 Suppl 118:29-35.
27. 27. Tobón GJ, Correa PA, Anaya JM. Anti-cyclic citrullinated peptide antibodies in patients with primary Sjögren's syndrome. Ann Rheum Dis 2005;64:791-2.
28. 28. van Noord C, Hooijkaas H, Dufour-van den Goorbergh BC, van Hagen PM, van Daele PLA, van de Merwe JP. Diagnostic value of anti-cyclic citrullinated peptide antibodies to detect rheumatoid arthritis in patients with Sjögren's syndrome. Ann Rheum Dis 2005;64:160-2.
29. 29. Barcelos F, Abreu I, Patto JV, Trindade H, Teixeira A. Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in Sjögren's syndrome. Acta Reumatol Port 2009;34:608-12.
30. 30. Kim SM, Park E, Lee JH, Lee SH, Kim HR. The clinical significance of anti-cyclic citrullinated peptide antibody in primary Sjögren syndrome. Rheumatol Int 2012;32:3963-7.